TRIMPEX
LOE ApproachingNDAORALTABLET
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIMPEX is an oral small-molecule tablet approved by Roche in 1980 with an unknown mechanism of action and indication profile. The generic name and pharmacologic class remain unspecified in available data. Patient populations and therapeutic uses cannot be determined without additional clinical documentation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a mature brand team likely focused on lifecycle management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate a stable, small team structure with limited growth headroom. Roles available are typically defensive in nature—focused on managing decline, optimizing pricing, and preparing for generic entry. Career progression on this product is constrained; mobility to growth-stage brands may be necessary for advancement.
Brand ManagerSenior Brand Manager
Worked on TRIMPEX at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.